Lixte Biotechnology Holdings Inc (LIXT)
2.460
+0.08
(+3.38%)
USD |
NASDAQ |
May 17, 16:00
2.29
-0.17
(-6.93%)
After-Hours: 20:00
Lixte Biotechnology Holdings Research and Development Expense (Annual): 0.8981M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.8981M |
| December 31, 2022 | 1.349M |
| December 31, 2021 | 1.737M |
| December 31, 2020 | 1.224M |
| December 31, 2019 | 0.8209M |
| December 31, 2018 | 0.0407M |
| December 31, 2017 | 0.4673M |
| December 31, 2016 | 0.87M |
| December 31, 2015 | 2.092M |
| Date | Value |
|---|---|
| December 31, 2014 | 1.118M |
| December 31, 2013 | 0.8799M |
| December 31, 2012 | 1.012M |
| December 31, 2011 | 1.335M |
| December 31, 2010 | 0.4455M |
| December 31, 2009 | 0.4965M |
| December 31, 2008 | 0.6087M |
| December 31, 2007 | 0.4238M |
| December 31, 2006 | 0.1806M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
0.8209M
Minimum
2019
1.737M
Maximum
2021
1.206M
Average
1.224M
Median
2020
Research and Development Expense (Annual) Benchmarks
| iBio Inc | 10.33M |
| PAVmed Inc | 14.28M |
| Moleculin Biotech Inc | 19.49M |
| Syros Pharmaceuticals Inc | 108.15M |
| Nutriband Inc | 1.960M |